Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: A meta-analysis

Journal of the National Cancer Institute

Volumn 105, Issue 21, 2013, Pages 1600-1607

  Oba, Koji ^a   Paoletti, Xavier ^b   Alberts, Steven ^c   Bang, Yung Jue ^d   Benedetti, Jacqueline ^e   Bleiberg, Harry ^f   Catalano, Paul ^g   Lordick, Florian ^h   Michiels, Stefan ⁱ   Morita, Satoshi ^j   Ohashi, Yasuo ^k   Pignon, Jean Pierre ⁱ   Rougier, Philippe ^l   Sasako, Mitsuru ^m   Sakamoto, Junichi ⁿ   Sargent, Daniel ^c   Shitara, Kohei ^o   Van Cutsem, Eric ^p   Buyse, Marc ^q,r   Burzykowski, Tomasz ^q,r  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b INSERM U900   (France)

^c MAYO CLINIC   (United States)

^d Seoul National University College of Medicine   (South Korea)

^e SWOG STATISTICAL CENTER   (United States)

^f Harvard School of Public Health ^*

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY HOSPITAL LEIPZIG   (Germany)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j YOKOHAMA CITY UNIVERSITY   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^m HYOGO COLLEGE OF MEDICINE   (Japan)

ⁿ Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^o NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^q INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^r HASSELT UNIVERSITY   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EXTERNAL VALIDITY; FOLLOW UP; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; STOMACH CANCER; SURVIVAL PREDICTION; VALIDATION STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890468324     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt270     Document Type: Review

References (32)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
2. Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315-321.
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-730.
5. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387-4393.
6. The GASTRIC group. Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-Analysis. JAMA. 2010;303(17):1729-1737.
7. Buyse M, Burzykowski T, Michiels S, Carroll K. Individual-And trial-level surrogacy in colorectal cancer. Stat Methods Med Res. 2008;17(5):467-475.
8. Mauguen A, Pignon J-P, Burdett S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-Analysis of meta-Analyses of individual patients' data. Lancet Oncol. 2013;14(7):619-626.
9. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-Analyses of randomized experiments. Biostatistics. 2000;1(1):49-67.
10. Burzykowski T, Molenberghs G, Buyse M. The Evaluation of Surrogate Endpoints. New York: Springer; 2006
11. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc Ser C Appl Statist. 2001;50(4):405-422.
12. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987-1992.
13. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100(6):388-398.
14. De Vita F, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: A randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol. 2007;18(8):1354-1358.
15. Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol. 1999;17(12):3810-3815.
16. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-Analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815-2834.
17. Burzykowski T, Buyse M. Surrogate threshold effect: An alternative measure for meta-Analytic surrogate endpoint validation. Pharm Statist. 2006;5(3):173-186.
18. The Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer. 1982;49(6):1116-1122.
19. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13(2):299-307.
20. Coombes RC, Schein PS, Chilvers CE, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol. 1990;8(8):1362-1369.
21. Bouché O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16(9):1488-1497.
22. Engstrom PF, MacIntyre JM, Douglass HO, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: A phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982;49(8):1555-1560.
23. Krook JE, O'Connell MJ, Wieand HS, et al. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer. 1991;67(10):2454- 2458.
24. Lise M, Nitti D, Marchet A, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol. 1995;13(11):2757-2763.
25. Macdonald JS, Fleming TR, Peterson RF, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol. 1995;2(6):488-494.
26. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-Tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94(12):1468-1476.
27. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: A randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999;354(9175):273-277.
28. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21(12):2282-2287.
29. Nitti D, Wils J, Dos Santos JG, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006;17(2):262-269.
30. Tsavaris NB, Tentas K, Kosmidis P, et al. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial. Am J Clin Oncol. 1996;19(5):517-521.
31. The GASTRIC Group. Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-Analysis. Eur J Cancer. 2013;49(7):1565-1577.
32. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664-8670.